Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer

Qing Li(Army Medical University), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiayu Wang(Nanjing University of Chinese Medicine), Qiao Li(Guangzhou University of Chinese Medicine), Yang Luo(Chongqing University of Posts and Telecommunications), Tongtong Zhang(South China Agricultural University), Pin Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiani Wang(Hubei University of Technology), Ying Fan(Hebei North University), Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Han(Fujian University of Traditional Chinese Medicine), Yuxin Mu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Chinese Journal of Cancer Research
January 1, 2020
10.21147/j.issn.1000-9604.2020.04.06
Cited by 11

Related Papers

Targeted therapeutic options and future perspectives for HER2-positive breast cancer
|Signal Transduction and Targeted Therapy|2019|406
In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities
|Frontiers in Pharmacology|2019|287
Circular RNA SAMD4A controls adipogenesis in obesity through the miR-138-5p/EZH2 axis
|Theranostics|2020|128
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
|Chinese Journal of Cancer Research|2019|126
In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
|Frontiers in Oncology|2022|119